YKL-40 expression in human hepatocellular carcinoma: A potential biomarker?

Hepatobiliary and Pancreatic Diseases International

Volumn 10, Issue 6, 2011, Pages 605-610

  Xiao, Xin Qiang ^a   Hassanein, Tarek ^b   Li, Qun Fang ^a   Liu, Wei ^a   Zheng, Yu Huang ^a   Chen, Jun ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cirrhosis; Hepatocellular carcinoma; Ykl 40

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; PROTEIN; PROTEIN YKL 40; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TISSUE LEVEL;

EID: 83055191301     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1499-3872(11)60103-3     Document Type: Article

References (21)

1. Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010;15:5-13.
2. Long J, Lang ZW, Wang HG, Wang TL, Wang BE, Liu SQ. Glutamine synthetase as an early marker for hepatocellular carcinoma based on proteomic analysis of resected small hepatocellular carcinomas. Hepatobiliary Pancreat Dis Int 2010;9:296-305.
3. Tian L, Wang Y, Xu D, Gui J, Jia X, Tong H, et al. Serological AFP/ golgi protein 73 could be a new diagnostic parameter of hepatic diseases. Int J Cancer 2010 Dec 7.
4. El-Attar HA, Kandil MH, El-Kerm YM, El-Ghandour MK. Comparison of serum survivin and alpha fetoprotein in Egyptian patients with hepatocellular carcinoma associated with hepatitis C viral infection. Asian Pac J Cancer Prev 2010; 11:897-903.
5. Cabrera R, Nelson DR. Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther 2010;31: 461-476.
6. Malaguarnera G, Giordano M, Paladina I, Berretta M, Cappellani A, Malaguarnera M. Serum markers of hepatocellular carcinoma. Dig Dis Sci 2010;55:2744-2755.
7. Johansen JS, Høyer PE, Larsen LA, Price PA, Møllgård K. YKL-40 protein expression in the early developing human musculoskeletal system. J Histochem Cytochem 2007;55: 1213-1228.
8. Horbinski C, Wang G, Wiley CA. YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas. Int J Clin Exp Pathol 2010;3:226-237.
9. Thöm I, Andritzky B, Schuch G, Burkholder I, Edler L, Johansen JS, et al. Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. Cancer 2010;116:4114-4121.
10. Johansen JS, Schultz NA, Jensen BV. Plasma YKL-40: a potential new cancer biomarker? Future Oncol 2009;5:1065-1082.
11. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29:e45.
12. Lee KG, Seo YS, An H, Um SH, Jung ES, Keum B, et al. Usefulness of non-invasive markers for predicting liver cirrhosis in patients with chronic hepatitis B. J Gastroenterol Hepatol 2010;25:94-100.
13. Berres ML, Papen S, Pauels K, Schmitz P, Zaldivar MM, Hellerbrand C, et al. A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. J Hepatol 2009;50:370-376.
14. Pungpapong S, Nunes DP, Krishna M, Nakhleh R, Chambers K, Ghabril M, et al. Serum fibrosis markers can predict rapid fibrosis progression after liver transplantation for hepatitis C. Liver Transpl 2008;14:1294-1302.
15. Saitou Y, Shiraki K, Yamanaka Y, Yamaguchi Y, Kawakita T, Yamamoto N, et al. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol 2005;11:476-481.
16. Nøjgaard C, Johansen JS, Christensen E, Skovgaard LT, Price PA, Becker U, et al. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J Hepatol 2003;39:179-186.
17. Shao R, Hamel K, Petersen L, Cao QJ, Arenas RB, Bigelow C, et al. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene 2009;28:4456-4468.
18. Yang GF, Cai PY, Li XM, Deng HX, He WP, Xie D. Expression and clinical significance of YKL-40 protein in epithelial ovarian cancer tissues. Ai Zheng 2009;28:142-145.
19. Ku BM, Lee YK, Ryu J, Jeong JY, Choi J, Eun KM, et al. CHI3L1 (YKL-40) is expressed in human gliomas and regulates the invasion, growth and survival of glioma cells. Int J Cancer 2011;128:1316-1326.
20. Taimr P, Higuchi H, Kocova E, Rippe RA, Friedman S, Gores GJ. Activated stellate cells express the TRAIL receptor-2/ death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology 2003;37:87-95.
21. Lau SH, Sham JS, Xie D, Tzang CH, Tang D, Ma N, et al. Clusterin plays an important role in hepatocellular carcinoma metastasis. Oncogene 2006;25:1242-1250.